Covered recipient · General Payments record
ANIRUDHA DASGUPTA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$6,633.71
186 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,266.44 | 178 |
| Consulting Fee | $2,800.00 | 1 |
| Travel and Lodging | $518.18 | 2 |
| Education | $49.09 | 5 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 4 of 4; records 151–186 of 186 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ANIRUDHA DASGUPTA
NPI 1841298387 · CMS profile ID 129356
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
KINGWOOD, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–186 of 186 matching records. This page contains 36 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1841298387?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ANIRUDHA DASGUPTA, NPI 1841298387, CMS profile ID 129356. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–186 of 186 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841298387?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). ANIRUDHA DASGUPTA, NPI 1841298387, CMS profile ID 129356. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–186 of 186 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841298387?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- ANIRUDHA DASGUPTA, NPI 1841298387, CMS profile ID 129356, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–186 of 186 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1841298387?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
186 matching records · $6,633.71 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–186 of 186.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Exelixis Inc. | $28.55 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686551509 | CMS |
| GENZYME CORPORATION | $12.26 | 02/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693932623 | CMS |
| E.R. Squibb & Sons, L.L.C. | $12.35 | 02/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651281135 | CMS |
| Merck Sharp & Dohme Corporation | $12.25 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695907157 | CMS |
| Genentech USA, Inc. | $23.79 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681219813 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.36 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697384671 | CMS |
| EISAI INC. | $18.46 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 696997109 | CMS |
| Merck Sharp & Dohme Corporation | $16.56 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695248343 | CMS |
| Agios Pharmaceuticals, Inc. | $13.23 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701353197 | CMS |
| Celgene Corporation | $20.03 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672731447 | CMS |
| Merck Sharp & Dohme Corporation | $17.31 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695921121 | CMS |
| EMD Serono, Inc. | $16.19 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 702984807 | CMS |
| E.R. Squibb & Sons, L.L.C. | $112.97 | 01/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651281131 | CMS |
| Amgen Inc. | $15.83 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662181779 | CMS |
| Incyte Corporation | $12.74 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666253217 | CMS |
| Janssen Biotech, Inc. | $20.33 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658390505 | CMS |
| EISAI INC. | $12.06 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 696996595 | CMS |
| Janssen Biotech, Inc. | $19.19 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658390501 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $22.68 | 01/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700295159 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.16 | 01/21/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700295161 | CMS |
| E.R. Squibb & Sons, L.L.C. | $16.47 | 01/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651281133 | CMS |
| Amgen Inc. | $19.26 | 01/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662181777 | CMS |
| Array BioPharma Inc. | $14.88 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700971983 | CMS |
| Lilly USA, LLC | $13.87 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657694799 | CMS |
| Novartis Pharmaceuticals Corporation | $17.96 | 01/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658840713 | CMS |
| PFIZER INC. | $13.75 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671901843 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7.08 | 01/04/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700295149 | CMS |
| Merck Sharp & Dohme Corporation | $13.27 | 01/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695262549 | CMS |
| Novartis Pharmaceuticals Corporation | $18.86 | 01/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658840705 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.23 | 01/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685106301 | CMS |
| AstraZeneca Pharmaceuticals LP | $218.90 | 01/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685396461 | CMS |
| AstraZeneca Pharmaceuticals LP | $36.06 | 01/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685576465 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.84 | 01/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685686095 | CMS |
| AstraZeneca Pharmaceuticals LP | $115.63 | 01/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685746575 | CMS |
| AstraZeneca Pharmaceuticals LP | $299.28 | 01/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685903577 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.42 | 01/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685999261 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,193,182.53 | 68 |
| PY2024 | Principal investigator | $1,743,640.62 | 38 |
| PY2023 | Principal investigator | $1,449,736.14 | 28 |
| PY2022 | Principal investigator | $1,131,352.38 | 27 |
| PY2021 | Principal investigator | $519,791.96 | 26 |
| PY2020 | Principal investigator | $465,502.85 | 17 |
| PY2019 | Recipient | $108.40 | 1 |
| PY2019 | Principal investigator | $829,812.80 | 19 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
68 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,497.86 | 12/31/2025 | Non-covered Recipient Entity Millennium Research & Clinical Development | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast | No dispute reported | 06/30/2026 | 1232927563 |
| Principal investigator 1 | BioNTech SE | $1,971.15 | 12/19/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | BNT327 | No dispute reported | 06/30/2026 | 1249011912 |
| Principal investigator 1 | BioNTech SE | $7,884.60 | 11/20/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | BNT327 | No dispute reported | 06/30/2026 | 1249011914 |
| Principal investigator 1 | BioNTech SE | $12,564.70 | 11/20/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327 | No dispute reported | 06/30/2026 | 1249020583 |
| Principal investigator 1 | BioNTech SE | $4,041.75 | 11/07/2025 | Non-covered Recipient Entity TEXAS ONCOLOGY PA | BNT327 | No dispute reported | 06/30/2026 | 1249011916 |
| Principal investigator 1 | BioNTech SE | $92.00 | 11/01/2025 | Non-covered Recipient Entity Texas Oncology, P. A. | BNT327-03 | No dispute reported | 06/30/2026 | 1249011918 |
| Principal investigator 1 | BioNTech SE | $92.00 | 11/01/2025 | Non-covered Recipient Entity Texas Oncology, P. A. | BNT327-03 | No dispute reported | 06/30/2026 | 1249011954 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $30,960.00 | 10/24/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1185554256 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $57,718.85 | 10/17/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer | No dispute reported | 06/30/2026 | 1185554264 |
| Principal investigator 1 | BioNTech SE | $1,459.55 | 09/04/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020559 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,750.00 | 09/03/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | No dispute reported | 06/30/2026 | 1185554266 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $400.00 | 08/12/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233741030 |
| Principal investigator 1 | BioNTech SE | $7,369.00 | 08/07/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020561 |
| Principal investigator 1 | BioNTech SE | $325.00 | 08/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249014137 |
| Principal investigator 1 | BioNTech SE | $5,421.30 | 07/04/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020557 |
| Principal investigator 1 | AstraZeneca UK Limited | $6,500.00 | 06/27/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2) | No dispute reported | 06/30/2026 | 1185554260 |
| Principal investigator 1 | BioNTech SE | $4,466.00 | 06/24/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020509 |
| Principal investigator 1 | BioNTech SE | $1,111.80 | 06/19/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020485 |
| Principal investigator 1 | BioNTech SE | $41,729.05 | 06/19/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249020487 |
| Principal investigator 1 | BioNTech SE | $4,466.00 | 06/19/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249020491 |
| Principal investigator 1 | BioNTech SE | $1,111.80 | 06/05/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020483 |
| Principal investigator 1 | BioNTech SE | $3,676.25 | 05/28/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249020481 |
| Principal investigator 1 | BioNTech SE | $12,959.95 | 05/27/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020479 |
| Principal investigator 1 | BioNTech SE | $9,351.00 | 05/27/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249020489 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,760.00 | 05/22/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233741028 |
| Principal investigator 1 | BioNTech SE | $9,351.00 | 05/15/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020507 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $61,737.37 | 05/07/2025 | Non-covered Recipient Entity WALDRON MEDICAL RESEARCH & DEVELOPMENT, LLC | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1185554250 |
| Principal investigator 1 | BioNTech SE | $9,960.30 | 04/23/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020475 |
| Principal investigator 1 | BioNTech SE | $8,647.05 | 04/23/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249020477 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $4,500.00 | 04/16/2025 | Non-covered Recipient Entity Millennium Research & Clinical Development | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast | No dispute reported | 06/30/2026 | 1232927561 |
| Principal investigator 1 | BioNTech SE | $25,824.70 | 04/15/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249020473 |
| Principal investigator 1 | BioNTech SE | $450.00 | 04/10/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020493 |
| Principal investigator 1 | BioNTech SE | $3,000.00 | 04/10/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020495 |
| Principal investigator 1 | BioNTech SE | $3,500.00 | 04/10/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020497 |
| Principal investigator 1 | BioNTech SE | $12,000.00 | 04/10/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020499 |
| Principal investigator 1 | BioNTech SE | $2,903.00 | 04/08/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020501 |
| Principal investigator 1 | BioNTech SE | $6,448.00 | 04/08/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020503 |
| Principal investigator 1 | BioNTech SE | $9,351.00 | 04/08/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-07 | No dispute reported | 06/30/2026 | 1249020505 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $29,750.00 | 04/02/2025 | Non-covered Recipient Entity WALDRON MEDICAL RESEARCH & DEVELOPMENT, LLC | A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum Based Chemotherapy for First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer NSCLC POSEIDON | No dispute reported | 06/30/2026 | 1185554270 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $18,155.00 | 03/28/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | A Phase 1b2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan T-DXd Monotherapy and Combinations in Adult Participants with HER2 Overexpressing Gastric Cancer DESTINY-Gastric03 | No dispute reported | 06/30/2026 | 1185554244 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $20,460.00 | 03/26/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) | No dispute reported | 06/30/2026 | 1185554240 |
| Principal investigator 1 | BioNTech SE | $3,500.00 | 02/25/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249020665 |
| Principal investigator 1 | BioNTech SE | $450.00 | 02/25/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249020667 |
| Principal investigator 1 | BioNTech SE | $3,000.00 | 02/25/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249020669 |
| Principal investigator 1 | BioNTech SE | $12,000.00 | 02/25/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249020671 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $16,500.00 | 02/13/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | No dispute reported | 06/30/2026 | 1233741026 |
| Principal investigator 1 | BioNTech SE | $3,950.00 | 02/05/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249020659 |
| Principal investigator 1 | BioNTech SE | $3,000.00 | 02/05/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249020661 |
| Principal investigator 1 | BioNTech SE | $12,000.00 | 02/05/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH AND CLINICAL DEVELOPMENT LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249020663 |
| Principal investigator 1 | BioNTech SE | $72.73 | 02/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249014125 |
| Principal investigator 1 | BioNTech SE | $42.00 | 02/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249014127 |
| Principal investigator 1 | BioNTech SE | $98.10 | 02/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249014129 |
| Principal investigator 1 | BioNTech SE | $330.00 | 02/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249014131 |
| Principal investigator 1 | BioNTech SE | $97.00 | 02/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249014133 |
| Principal investigator 1 | BioNTech SE | $85.00 | 02/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249014135 |
| Principal investigator 1 | BioNTech SE | $330.00 | 02/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249014153 |
| Principal investigator 1 | BioNTech SE | $97.00 | 02/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-06 | No dispute reported | 06/30/2026 | 1249014155 |
| Principal investigator 1 | BioNTech SE | $97.00 | 02/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249014157 |
| Principal investigator 1 | BioNTech SE | $97.00 | 02/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249014159 |
| Principal investigator 1 | BioNTech SE | $85.00 | 02/01/2025 | Non-covered Recipient Entity Millennium Research and Clinical Development, LLC | BNT327-03 | No dispute reported | 06/30/2026 | 1249014161 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $46,452.40 | 01/31/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | No dispute reported | 06/30/2026 | 1185554248 |
| Principal investigator 1 | AstraZeneca UK Limited | $23,793.00 | 01/31/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) | No dispute reported | 06/30/2026 | 1185554262 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $176,075.11 | 01/24/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185554268 |
| Principal investigator 1 | AstraZeneca UK Limited | $119,165.34 | 01/15/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY | No dispute reported | 06/30/2026 | 1185554242 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $139,604.24 | 01/13/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185554254 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $62,711.39 | 01/03/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) | No dispute reported | 06/30/2026 | 1185554246 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $91,396.76 | 01/03/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185554252 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,436.43 | 01/03/2025 | Non-covered Recipient Entity MILLENNIUM RESEARCH & CLINICAL DEVELOPMENT, LLC | Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) | No dispute reported | 06/30/2026 | 1185554258 |